Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Beam Therapeutics heads into its November earnings with short sellers adding steadily, the stock under pressure, and the entire gene-editing cohort in retreat.
Short interest is the defining feature of the BEAM setup right now. Bears hold 27.8% of the free float, a position that has grown roughly 13% over the past month and 5.7% over the past week alone. FINRA's fortnightly official figure, settling on September 30, put shares short at 27.5 million, implying a days-to-cover reading of 15.3, meaning shorts would need more than three trading weeks of average volume to unwind. That is a structurally large position for a clinical-stage biotech. Despite the size of the short, the borrow market tells a different story: cost to borrow has eased to 0.42%, down nearly 19% on the week, and availability stands at 216% of short interest, meaning roughly two shares remain available for every one already lent out. Availability is well off its tightest point of 95.6% recorded over the past year, with ample room in the lending pool for new shorts to build without a squeeze risk. The ORTEX short score of 76.1 ranks in the 6th percentile of the broader universe, flagging this as one of the more heavily shorted names in the market.
Options positioning offers no counterweight. The put/call ratio of 0.279 is fractionally below its 20-day average of 0.284, essentially flat and well below the 52-week high of 0.512. Call activity dominates volume, which at first glance looks bullish, but in the context of a heavily shorted clinical-stage name with an approaching earnings date, a low PCR often reflects speculative call-buying rather than genuine institutional confidence. The z-score of -0.28 confirms there is no statistically notable shift in options positioning either way.
The Street remains constructive in print, even if the price tells another story. Wedbush reiterated its Outperform rating with a $65 target as recently as today. HC Wainwright holds a $80 target and a Buy. Citi raised its target to $68 earlier in the year. The mean analyst price target is $52.15, roughly 113% above the current price of $24.43. That gap is the source of the tension: sell-side models price in a pipeline that delivers, while the market, via a 27.8% short position and a stock off 3.2% on the week, has not yet accepted that framing. RBC sits at the other end of the spectrum with a Sector Perform and a $26 target, close to where the stock trades. The forward earnings yield of -0.19 and price-to-book of 2.65 reflect a company valued on its option value, not current financials. EPS momentum scores sit around the 50th percentile, neither gaining nor losing ground versus expectations.
The bull case rests on BEAM-302 in alpha-1 antitrypsin deficiency, where 18-month durability data in 29 patients has shown mean steady-state total AAT of 14.4 micromolar at the 60mg dose, above the 11 micromolar protective threshold, alongside a BLA submission for risto-cel potentially before year-end 2026. The company carries $1.15 billion in cash, providing runway into mid-2029. The bear case is built around four years of "show-me mode" from the market, the company's own management has acknowledged it, alongside clinical risk across a base-editing platform where a safety signal in any programme could impair confidence in all of them. The bear case also bakes in assumed annual dilution of $200 million from 2027.
The institutional register shows active hands staying put. ARK Investment Management added 1.06 million shares in the latest quarter, bringing its stake to 10.2% of shares. FMR added 441,000 shares to hold 11.8%. T. Rowe added 702,000 shares. These are not passive flows. Against that, Wikipedia attention for BEAM spiked to a z-score of 2.1 relative to its own 90-day history as of late September, suggesting retail interest picked up around that time, though the stock has since drifted lower.
The cohort picture is uniformly weak. CRSP fell 7.2% on the week, EDIT dropped 10.4%, SANA shed 12.4%, and RXRX lost 17.2%. BEAM's 3.2% weekly decline looks contained by comparison, but the group is experiencing broad de-risking. With Q3 results due November 4, the next three weeks will be defined by whether any pipeline update around risto-cel or BEAM-302 changes the narrative before the print, or whether short interest continues to build into the release.
See the live data behind this article on ORTEX.
Open BEAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
